The breadth of policy reforms has varied dramatically across countries. In a few, there has been rapid structural change, whereas in a greater number of countries, changes have been limited to parametric change (reductions in salaries, pharmaceutical prices, increases in co-payments). The most common changes have been to reform pharmaceuticals both to pay less at a national level and to encourage more use of generics, increase co-payments, and to centralise purchasing or provision of health goods and services. That said, a number of reforms have attracted considerable critique and political unrest among workers, industry and the general population.